Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways

Table 1

Correlation between CHD5 expression levels and clinicopathological features in RCC patients.

Variables	Number (%)	mRNA^a ()	value	Protein^b ()	value
Gender
Male	17 (70.8)		0.573		0.508
Female	7 (29.2)
Age
<60	14 (58.3)		0.071		0.101
≥60	10 (41.7)
Tumor size
<7	14 (58.3)		0.069		0.061
≥7	10 (41.7)
TNM stage
I-II	13 (54.2)		<0.001		0.008
III-IV	11 (45.8)
Fuhrman grade
I-II	12 (50.0)		0.004		0.057
III-IV	12 (50.0)
Lymph node metastasis
Yes	6 (25.0)		0.002		0.028
No	18 (75.0)

^aRelative expression of CHD5 ratio by RT-qPCR. ^bGrayscale ratio by western blot.